Clovis Oncology Inc Revenue Growth Rates (CLVS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Clovis Oncology inc   (NASDAQ: CLVS)
 

CLVS's Revenue Growth by Quarter and Year

Clovis Oncology Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CLVS Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 30.66
2nd Quarter June 32.14
1st Quarter March 34.25
FY 97.05

CLVSs Annual Revenue
Clovis Oncology Inc 's Revenue in the fiscal year 2021 $ 148.76 millions
Clovis Oncology Inc 's Revenue in the fiscal year 2020 $ 164.52 millions
Clovis Oncology Inc 's Revenue in the fiscal year 2019 $ 143.01 millions
Clovis Oncology Inc 's Revenue in the fiscal year 2018 $ 95.39 millions
Clovis Oncology Inc 's Revenue in the fiscal year 2017 $ 55.51 millions




CLVS Revenue third quarter 2022 Y/Y Growth Comment
Clovis Oncology Inc reported decline in Revenue in the third quarter 2022 by -19.14% to $ 30.66 millions, from the same quarter in 2021.
The contraction in the third quarter 2022 Clovis Oncology Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 1003.68%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 197 other companies have achieved higher Revenue growth. While Clovis Oncology Inc ' s Revenue fall of -19.14% ranks overall at the positon no. 3503 in the third quarter 2022.


CLVS Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - -16.93 % 10.15 % 29.52 %
3rd Quarter September -19.14 % -2.19 % 3.11 % 65.2 %
2nd Quarter June -12.71 % -7.7 % 20.95 % 38.8 %
1st Quarter March -9.99 % -10.6 % 28.5 % 78.83 %
FY   - -9.58 % 15.04 % -

Financial Statements
Clovis Oncology Inc 's third quarter 2022 Revenue $ 30.66 millions CLVS's Income Statement
Clovis Oncology Inc 's third quarter 2021 Revenue $ 37.92 millions Quarterly CLVS's Income Statement


CLVS Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - -5.14 % 11.68 % 4.55 %
3rd Quarter September -4.6 % 2.99 % -2.81 % 14.01 %
2nd Quarter June -6.16 % -3.23 % -6.27 % -0.42 %
1st Quarter March -4.78 % -12.12 % 8.27 % 9.13 %
FY (Year on Year)   - -9.58 % 15.04 % -


Back to CLVS Growth rate Comparisons >> Back to CLVS Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #198
Healthcare Sector #528
Overall #3503

Revenue Y/Y Growth Statistics
High Average Low
21746.15 % 1003.68 % -100 %
(Dec 31 2017)   (Dec 31 2015)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #198
Healthcare Sector #528
Overall #3503
Revenue Y/Y Growth Statistics
High Average Low
21746.15 % 1003.68 % -100 %
(Dec 31 2017)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Clovis Oncology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
8932.05 % 357.08 % -100 %
(Mar 31 2017)  


CLVS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Clovis Oncology Inc disclosed fall in Revenue from the second quarter by -4.6% to $ 30.66 millions, from $ 32.14 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2022 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 188 other companies have achieved higher Revenue quarter on quarter growth. While Clovis Oncology Inc 's Revenue growth quarter on quarter, overall rank is 3179.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #189
Healthcare Sector #481
Overall #3179
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #189
Healthcare Sector #481
Overall #3179
Revenue Q/Q Growth Statistics
High Average Low
8932.05 % 357.08 % -100 %
(Mar 31 2017)  


CLVS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Clovis Oncology Inc disclosed fall in Revenue from the second quarter by -4.6% to $ 30.66 millions, from $ 32.14 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2022 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 188 other companies have achieved higher Revenue quarter on quarter growth. While Clovis Oncology Inc 's Revenue growth quarter on quarter, overall rank is 3179.


Clovis Oncology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 133.02 $ 140.27 $ 144.95 $ 148.76 $ 156.09
Y / Y Revenue Growth (TTM) -14.78 % -10.62 % -9.41 % -9.58 % -2.77 %
Year on Year Revenue Growth Overall Ranking # 2889 # 1844 # 1701 # 2157 # 1726
Seqeuential Revenue Change (TTM) -5.17 % -3.23 % -2.56 % -4.7 % -0.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 2789 # 1897 # 1707 # 3384 # 2520


Cumulative Revenue growth Comment
Clovis Oncology Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -14.78% year on year, at Sep 30 2022 compare to the -10.62% decrease at Jun 30 2022. If the Clovis Oncology Inc 's fiscal year would end at Sep 30 2022, annual Revenue would be $133 millions.

In the Healthcare sector 396 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1844 to 2889.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 144
Healthcare Sector # 397
Overall # 2889

Revenue TTM Y/Y Growth Statistics
High Average Low
112.92 %
 28.36 %
-14.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 144
Sector # 385
S&P 500 # 2789
Cumulative Revenue growth Comment
Clovis Oncology Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -14.78% year on year, at Sep 30 2022 compare to the -10.62% decrease at Jun 30 2022. If the Clovis Oncology Inc 's fiscal year would end at Sep 30 2022, annual Revenue would be $133 millions.

In the Healthcare sector 396 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1844 to 2889.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 144
Healthcare Sector # 397
Overall # 2889

Revenue TTM Y/Y Growth Statistics
High Average Low
112.92 %
28.36 %
-14.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 144
Sector # 385
S&P 500 # 2789




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CLVS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Nrc Health-0.20%$ -0.201 millions
Livanova Plc-0.24%$ -0.241 millions
Healthcare Services Group Inc -0.27%$ -0.265 millions
Catalent Inc -0.29%$ -0.293 millions
Asensus Surgical Inc -0.31%$ -0.311 millions
Liquidia Corporation-0.43%$ -0.429 millions
Integra Lifesciences Holdings Corp-0.43%$ -0.432 millions
Pediatrix Medical Group Inc -0.62%$ -0.615 millions
China Pharma Holdings Inc-0.64%$ -0.642 millions
Acadia Pharmaceuticals Inc -0.68%$ -0.682 millions
Bausch and Lomb Corp-0.74%$ -0.738 millions
Amgen Inc -0.81%$ -0.805 millions
Syneos Health Inc -0.89%$ -0.891 millions
Hologic Inc-0.93%$ -0.925 millions
Innovage Holding Corp -1.07%$ -1.070 millions
Regen Biopharma Inc -1.09%$ -1.088 millions
Procyon Corporation-1.20%$ -1.200 millions
Precipio inc -1.38%$ -1.380 millions
Ati Physical Therapy Inc -1.40%$ -1.397 millions
Ocular Therapeutix Inc -1.55%$ -1.547 millions
Alpine Immune Sciences Inc -1.75%$ -1.750 millions
Surgalign Holdings Inc -1.79%$ -1.786 millions
Tenet Healthcare Corp-1.90%$ -1.900 millions
Teleflex Incorporated-1.92%$ -1.923 millions
Novocure Limited-1.95%$ -1.952 millions
Fresenius Medical Care Ag-1.99%$ -1.990 millions
Hca Healthcare Inc -2.00%$ -1.997 millions
Dynatronics Corporation-2.01%$ -2.014 millions
Royalty Pharma Plc-2.10%$ -2.101 millions
National Healthcare Corp-2.13%$ -2.130 millions


About Clovis Oncology Inc Revenue Growth Rates (CLVS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Clovis Oncology Inc (CIK 1466301).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-22-017027
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Clovis Oncology Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.